Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma

Pomerri, Fabio; Cervino, Anna Rita; Bunni, Faise Al; Evangelista, Laura; Muzzio, Pier Carlo

doi:10.1007/s11547-013-0323-6

Cited by 6 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the follow‐up of DTC, FDG PET/CT has a distinct role in the follow‐up of RAI negative thyroid cancer lesions with an elevated Tg level and has an impact on treatment planning and prognosis . Although there is substantial literature supporting the use of FDG PET/CT scan in patients with elevated Tg levels, there is no clear mention of the optimal timing and frequency of PET/CT studies in DTC .…”

Section: Discussionmentioning

confidence: 99%

Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Few studies have demonstrated a change in therapy management using PET/CT. [ 20 21 ] Although we did not intend to document it, we observed that many patients with thyroid bed or cervical lymph node recurrence had coexisting mediastinal lymphadenopathy or lung metastases that excluded radical local treatments.…”

Section: Discussionmentioning

confidence: 99%

“…[ 17 18 19 ] Few studies have demonstrated that PET/CT may change therapy management in a substantial number of patients. [ 20 21 ] DTC usually spreads to cervical and thoracic regions and distant bones with relative sparing of other visceral organs. The prevalence of metastasis to the other sites is low.…”

Section: Introductionmentioning

confidence: 99%

The utility of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan

et al. 2020

View full text Add to dashboard Cite

Purpose of the Study: 18 F-Fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is used in the management of recurrent differentiated thyroid cancer (DTC) patients presented with rising thyroglobulin (Tg) or anti-Tg antibody (Atg) levels and negative whole-body I-131 scan (WBS). We aimed to evaluate the utility of regional or limited PET/CT in a large population preset with variable Tg/(ATg) levels. Materials and Methods: In a retrospective study, we analyzed 137 PET/CT done on DTC patients presented with raised Tg/Atg and negative WBS. Retrospective evaluation of other available clinical information was done. Results: One hundred and thirty-seven patients aged 8–72 years (41 ± 17.7 years) were included in the study. Eighty-nine (64.9%) patients had positive findings on 18 F-FDG PET-CT. It included thyroid bed recurrence, cervical, mediastinal lymphadenopathy, lung, and bone lesions. In addition, 36 patients had metabolically inactive lung nodules detected on CT. Serum Tg and female sex were the only predictors for a positive PET scan. In most (97.1%) of the patients, the disease was limited to the neck and thoracic region. Conclusions: PET/CT is an excellent imaging modality for evaluating DTC patients presented with biochemical recurrence. It not only finds the disease in more than 80% of the patients but also detects distant metastatic disease, which precludes regional therapies. Lesions were noted mostly in the neck and thoracic region with very few distant skeletal metastases (4/137 patients). In most of the patients, routine vertex to mid-thigh imaging could be avoided.

show abstract

“…Furthermore, current applications extend to disease extension, including the detection of undifferentiated metastases (3), guidance of therapy assessments and prediction of prognosis (4)(5)(6). Some studies have shown that 18 F-FDG PET and 18 F-FDG PET/CT can induce changes in clinical management plans in 10-78% of patients with DTC (7)(8)(9)(10)(11)(12), thereby improving clinical judgment. In the Brazilian population, there has been only one study using 18 F-FDG PET/CT in thyroid cancer patients with negative WBS and positive sTg in a small patient sample (13).…”

Section: Introductionmentioning

confidence: 99%

Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

Yang

Maciel

Nakabashi

et al. 2017

Arch. Endocrinol. Metab.

View full text Add to dashboard Cite

Objective: To evaluate the clinical utility of 18 F-FDG PET/CT in patients with high-risk DTC. Subjects and methods: Single-center retrospective study with 74 patients with high-risk differentiated thyroid cancer (DTC), classified in 4 groups. Group 1: patients with positive sTg or TgAb, subdivided in Group 1A: negative RxWBS and no foci of metastases identified at conventional image (n = 9); Group 1B: RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level (n = 13); Group 2: patients with histological findings of aggressive DTC variants (n = 21) and Group 3: patients with positive RxWBS (n = 31). Results: 18 F-FDG PET/CT identified undifferentiated lesions and helped restage the disease in groups 1B and 2. The scan helped guide clinical judgment in 9/13 (69%) patients of group 1B, 10/21 (48%) patients of group 2 and 2/31 (6%) patients of group 3. There was no clinical benefit associated with group 1A. 18 F-FDG PET/CT was associated with progressive disease. Conclusion: 18 F-FDG PET/CT is a useful tool in the follow-up of patients with high-risk DTC, mainly in the group of RxWBS not compatible with suspicious foci at conventional image or not proportional to sTg level and in those with aggressive DTC variants. Additionally, this study showed that 18 F-FDG PET/CT was associated with progression and helped display undifferentiated lesions guiding clinical assessments regarding surgeries or expectant treatments. Arch Endocrinol Metab. 2017;61(5):416-25.

show abstract

Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma

Abstract: PET/CT can help select patients, who might benefit from a tailored therapy by improving the detection of local recurrences not apparent on neck US or metastases.

Cited by 6 publications

References 27 publications

Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival

Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival

The utility of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan

Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

Contact Info

Product

Resources

About

Therapeutic impact of 18F-FDG PET/CT in recurrent differentiated thyroid carcinoma

Abstract: PET/CT can help select patients, who might benefit from a tailored therapy by improving the detection of local recurrences not apparent on neck US or metastases.

Cited by 6 publications

References 27 publications

Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival

Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival

The utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan

Clinical utility of 18F-FDG PET/CT in the follow-up of a large cohort of patients with high-risk differentiated thyroid carcinoma

Contact Info

Product

Resources

About

The utility of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with biochemical recurrence and negative whole-body radioiodine scintigraphy and evaluation of the possible role of a limited regional scan